We now show that ATG, used as a single agent, is sufficient to significantly blunt proteinuria and attenuate the kidney disease progression in diabetic mice and that the main mechanism of action is through its binding to and activation of protein phosphatase 2 A (PP2A). This evidence concerns the gene PTPA and kidney disorder.